~~<i id='3C27C38E00'><strike id='3C27C38E00'><tt id='3C27C38E00'><pre id='3C27C38E00'></pre></tt></strike></i>~~

Home» leisure time» focus

focus

author：Wikipedia 2025-09-27 11:19:40 Page View：61535

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Newly revealed memo details efforts to keep Trump in power following election loss
Next article： Sports medicine is finally prioritizing gender equality

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

2:03FromlefttorightsplitshowsphotosofEmadShargi,MoradTahbazandSiamakNamaziHandoutAftermonthsofquietn

BioMarin wins approval for gene therapy to treat hemophilia A

AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

O'Shea Sibley was killed after expressing queer joy by voguing, activists say

3:10QueenJean,ofTrans-Liberation,speaksduringavigiltomemorializeO'ShaeSibleyatagasstation,Aug.4,2023